Prognostic Factors for Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Dexamethasone Implant
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To investigate the prognostic factors of visual and anatomic outcomes in patients with diabetic macularedema (DME) treated with intravitreal injection of dexamethasone implant. Methods: We retrospectively studied 32 eyes of 31 patients with DME for best-corrected visual acuity (BCVA),central macular thickness, and height and width of both intraretinal fluid (IRF) and subretinal fluid. Logisticregression analysis was used to examine correlations between the baseline characteristics and outcomes at3 and 6 months. Results: Baseline predictor of BCVA ≥20 / 40 at month 3 was short height of baseline IRF (p = 0.02), whilegood baseline BCVA was a predictor for month 6 (p = 0.01). Predictors of improvement in logarithm of minimumangle of resolution BCVA 0.2 at month 3 were the absence of baseline IRF and poor baseline BCVA (p= 0.02 and p = 0.009, respectively), while poor baseline BCVA was the sole predictor at month 6 (p = 0.01). Predictor of central macular thickness ≤300 μm at month 3 was younger age (p = 0.03), while the absence ofIRF was the predictor for BCVA improvement at month 6 (p = 0.02). BCVA ≤20 / 100 at month 3 was predictedby poor baseline BCVA (p = 0.01), and increased width of total IRF was the predictor at month 6 (p = 0.02). Predictor of loss of logarithm of minimum angle of resolution BCVA 0.2 at month 6 was increased width oftotal IRF at baseline (p = 0.04). Additional injection within 6 months was negatively associated with the presenceof baseline DME (p = 0.03). Conclusions: The visual and anatomical outcome of DME treatment with dexamethasone implant can be predictedby baseline visual acuity and IRF morphology.
Abstract
Purpose: To investigate the prognostic factors of visual and anatomic outcomes in patients with diabetic macularedema (DME) treated with intravitreal injection of dexamethasone implant. Methods: We retrospectively studied 32 eyes of 31 patients with DME for best-corrected visual acuity (BCVA),central macular thickness, and height and width of both intraretinal fluid (IRF) and subretinal fluid. Logisticregression analysis was used to examine correlations between the baseline characteristics and outcomes at3 and 6 months. Results: Baseline predictor of BCVA ≥20 / 40 at month 3 was short height of baseline IRF (p = 0.02), whilegood baseline BCVA was a predictor for month 6 (p = 0.01). Predictors of improvement in logarithm of minimumangle of resolution BCVA 0.2 at month 3 were the absence of baseline IRF and poor baseline BCVA (p= 0.02 and p = 0.009, respectively), while poor baseline BCVA was the sole predictor at month 6 (p = 0.01). Predictor of central macular thickness ≤300 μm at month 3 was younger age (p = 0.03), while the absence ofIRF was the predictor for BCVA improvement at month 6 (p = 0.02). BCVA ≤20 / 100 at month 3 was predictedby poor baseline BCVA (p = 0.01), and increased width of total IRF was the predictor at month 6 (p = 0.02). Predictor of loss of logarithm of minimum angle of resolution BCVA 0.2 at month 6 was increased width oftotal IRF at baseline (p = 0.04). Additional injection within 6 months was negatively associated with the presenceof baseline DME (p = 0.03). Conclusions: The visual and anatomical outcome of DME treatment with dexamethasone implant can be predictedby baseline visual acuity and IRF morphology.
참고문헌 (20)
- Klein R, "The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema", Ophthalmology, 91, pp.1464~1474 (1984)[DOI]
- Bhagat N, "Diabetic macular edema: pathogenesis and treatment", Surv Ophthalmol, 54, pp.1~32 (2009)[DOI]
- Dugel PU, "Dexamethasone intravitreal implant in the treatment of diabetic macular edema", Clin Ophthalmol, 9, pp.1321~1335 (2015)
- Zhioua I, "Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema", Retina, 35, pp.1429~1435 (2015)[DOI]
- Moon BG, "Efficacy and safety of a dexamethasone implant in patients with diabetic macular edema at tertiary centers in Korea", J Ophthalmol, 2016, pp.9810270~ (2016)
- Otani T, "Patterns of diabetic macular edema with optical coherence tomography", Am J Ophthalmol, 127, pp.688~693 (1999)[DOI]
- Kim BY, "Optical coherence tomographic patterns of diabetic macular edema", Am J Ophthalmol, 142, pp.405~412 (2006)[DOI]
- Seo KH, "Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns", Retina, 36, pp.588~595 (2016)[DOI]
- Mori Y, "Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema", PLoS One, 12, pp.e0175809~ (2017)[DOI]
- Giocanti-Auregan A, "Functional and anatomical outcomes in patients with serous retinal detachment in diabetic macular edema treated with ranibizumab", Invest Ophthalmol Vis Sci, 58, pp.797~800 (2017)[DOI]
- Pelosini L, "Optical coherence tomography may be used to predict visual acuity in patients with macular edema", Invest Ophthalmol Vis Sci, 52, pp.2741~2748 (2011)[DOI]
- Shimura M, "Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema", Am J Ophthalmol, 145, pp.854~861 (2008)[DOI]
- Shah SU, "Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema", Retina, 36, pp.1986~1996 (2016)[DOI]
- Sophie R, "Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab", Ophthalmology, 122, pp.1395~1401 (2015)[DOI]
- Ferris FL 3rd, "Macular edema: a complication of diabetic retinopathy", Surv Ophthalmol, 28(Suppl), pp.452~461 (1984)[DOI]
- Bressler SB, "Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab", Arch Ophthalmol, 130, pp.1153~1161 (2012)[DOI]
- Yanoff M, "Pathology of human cystoid macular edema", Surv Ophthalmol, 28(Suppl), pp.505~511 (1984)[DOI]
- Bringmann A, "Pathomechanisms of cystoid macular edema", Ophthalmic Res, 36, pp.241~249 (2004)[DOI]
- Spaide RF, "Retinal vascular cystoid macular edema: review and new theory", Retina, 36, pp.1823~1842 (2016)[DOI]
- Romero-Aroca P, "Diabetic macular edema pathophysiology: vasogenic versus inflammatory", J Diabetes Res, 2016, pp.2156273~ (2016)